Mixed signals cloud the orphan drug market [Yahoo! Finance]
Biohaven Ltd. Common Shares (BHVN)
Last biohaven ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Yahoo! Finance
Regulatory whiplash has hit orphan drug developers in recent months. On the one hand, the FDA has signaled broad support for rare drug development. On the other, it recently issued several high-profile denials for rare disease drugs, including Regenxbio's Hunter syndrome therapy. This disconnect between regulatory talk and action has created an unpredictable environment for drugmakers, according to a recent Evaluate report "There were mixed responses to a number of submissions to the FDA in 2025 in the orphan space. While it is too early to establish if this is a new pattern or a fundamental change in expectations, the impact of these decisions can add to uncertainty,” said Andreas Hadjivasiliou, manager of content strategy for Evaluate, in an email. Some failed drugs in this space appear to have faced stricter standards and, at times, contradictory feedback on trial design, raising the bar for a drug category that already struggles with trial complexity due to small patient po
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential [Yahoo! Finance]Yahoo! Finance
- This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash [Yahoo! Finance]Yahoo! Finance
- Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes EnrollmentPR Newswire
- Biohaven (BHVN) had its price target raised by TD Cowen from $15.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- Biohaven (BHVN) had its "strong-buy" rating reaffirmed by Raymond James Financial, Inc..MarketBeat
BHVN
Earnings
- 3/2/26 - Beat
BHVN
Sec Filings
- 3/19/26 - Form 4
- 3/13/26 - Form DEFA14A
- 3/13/26 - Form DEF
- BHVN's page on the SEC website